Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 35,419 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Muscle Invasive Bladder Cancer
Interventions: Durvalumab, Cisplatin, Gemcitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,063 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions: Placebo, Vanquix Auto-Injector (Diazepam Injection); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 86
States / cities: Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more

Conditions: Healthy Volunteers
Interventions: (2R,6R)-Hydroxynorketamine, Placebo; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer.
Interventions: G-202; Drug
Lead sponsor: GenSpera, Inc.; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza
Interventions: Fluzone® (IM), Fluzone® Intradermal (ID), 2011-2012 FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 34 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Glioblastoma Multiforme
Interventions: Bevacizumab and Temozolomide; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Human Papillomavirus Infections
Interventions: Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more

Conditions: Head and Neck Lymphedema
Interventions: FT-CC and Swallow Exercises, Swallow Exercises; Device · Other
Lead sponsor: Tactile Medical; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Epitheliod Malignant Pleural Mesothelioma
Interventions: Photodynamic Therapy, Radical Pleurectomy, Chemotherapy, Photofrin 2.0 mg/kg; Radiation · Procedure · Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 2
States / cities: Buffalo, New York • Philadelphia, Pennsylvania

Conditions: Graft Versus Host Disease, Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease
Interventions: Autologous mesenchymal stromal cells (MSCs); Biological
Lead sponsor: Emory University; Other
Eligibility: 12 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Fragile X Syndrome
Interventions: Acamprosate, Lovastatin, Minocycline, Placebo, Baclofen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Food Security, Produce Consumption
Interventions: Market vouchers; Behavioral
Lead sponsor: University of Wyoming; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Laramie, Wyoming

Conditions: Advanced Biliary Tract Cancer
Interventions: Nanoliposomal Irinotecan, Leucovorin, Fluorouracil; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana • St Louis, Missouri + 1 more

Conditions: Crohn Disease
Interventions: Ustekinumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more

Conditions: Dermatitis
Interventions: PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%, Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%, Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%, Silwet* DA-63 (Momentive) 1.5%, Sodium lauryl sulfate (Sigma Aldrich) 1.0%, Water (control); Other
Lead sponsor: Kimberly-Clark Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Irving, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Epratuzumab; Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 11 more

Conditions: Lung Cancer
Interventions: computed tomography, positron emission tomography; Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 3
States / cities: St Louis, Missouri • Dallas, Texas • Madison, Wisconsin

Conditions: Healthy
Interventions: Microneedle patch; Device
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 50 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Solid Cancer
Interventions: BAY73-4506 (Regorafenib, Stivarga); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: NDO Full-thickness Plicator, Sham Control; Device
Lead sponsor: NDO Surgical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 13
States / cities: Orange, California • San Ramon, California • Denver, Colorado + 8 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: South Miami, Florida • Austin, Texas

Conditions: Bacterial Vaginosis
Interventions: LACTIN-V, Placebo control substance; Drug
Lead sponsor: Osel, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Squamous Cell Carcinoma
Interventions: DaRT seeds; Device
Lead sponsor: Alpha Tau Medical LTD.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 23
States / cities: Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 16 more

Search by objective public record fields.

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Determining Swallow Outcomes in Head & Neck Lymphedema Subjects Receiving Early Intervention With Pneumatic Compression

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

BMT Autologous MSCs for GvHD

Neurophysiological and Acute Pharmacological Studies in FXS Patients

#WYMarketsMatter: Testing Two Farmers Market Voucher Strategies to Increase Food Security

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

Positron Emission Tomography Scan and CT Scan in Planning Radiation Therapy for Patients With Stage II or Stage III Non-Small Cell Lung Cancer

Racial/Ethnic Differences in Microneedle Response

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

A Study to Determine the Effectiveness of Endoscopic Full-Thickness Plication for the Treatment of GERD

A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes

Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma